



Biocon Limited

20th KM Hosur Road
Electronics City
Bangalore 560 100, India
T 91 80 2808 2808
F 91 80 2852 3423
CIN : L24234KA1978PLC003417

Date of submission: September 22, 2018

www.biocon.com

To The Secretary Listing Department BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code - 532523	To The Secretary Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050 Scrip Code- BIOCON
---	---

Dear Sir/Madam,

Sub: Biocon's Drug Substance Facility in Bangalore completes US FDA inspection with no observations.
Ref: Regulations 30 of SEBI Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015.

Pursuant to Regulation 30 of the SEBI LODR Regulations, 2015, please find below the "Company Statement" on the subject matter.

This is to inform you that the US FDA conducted a periodic cGMP inspection of our Drug Substance manufacturing site at Bangalore Campus from Sep 17 - 21, 2018. The weeklong audit concluded without any observations and no Form 483 was issued. The successful audit of this site reflects our strong commitment to cGMP compliance. - *Company Spokesperson*

We request you to kindly take this to your records as per the requirement of LODR and oblige.

Thanking You,
Yours faithfully
For Biocon Limited

Satish Kumar SS
Company Secretary and Compliance Officer